Compare Gilead Sciences, Inc. (GILD) vs Workday Inc (WDAY) Price & Performance

Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.

Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.

WDAY trades at $145.46, up 4.04% in the last session, with a bullish technical signal from moving averages and a consensus analyst price target of $157.30. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $2.62. Revenue growth remains robust, projected to reach $9.9 billion in 2026, while net income margin improved to 8.6% in 2025. Recent news highlights AI-driven expansion deals and partnership growth, though the stock faces a lawsuit over AI bias concerns.

WDAY presents a favorable risk-reward profile with strong fundamentals and analyst support, but investors must weigh competitive pressures and regulatory risks. The stock's current valuation at 44.18x P/E reflects growth expectations, yet persistent net cash outflows and high debt levels warrant caution. Upside potential hinges on execution of AI initiatives and sustained subscription revenue growth amid a volatile tech sector.